AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,792,559 | +8.3% | 2,368,378 | 0.0% | 0.69% | +7.8% |
| Q2 2023 | $110,579,569 | +22.0% | 2,368,378 | 0.0% | 0.64% | +29.8% |
| Q1 2023 | $90,614,142 | -30.2% | 2,368,378 | 0.0% | 0.49% | -36.7% |
| Q4 2022 | $129,787,114 | +60.9% | 2,368,378 | 0.0% | 0.78% | +47.5% |
| Q3 2022 | $80,643,000 | +7106.7% | 2,368,378 | +1900.7% | 0.53% | +8700.0% |
| Q2 2022 | $1,119,000 | -33.4% | 118,378 | 0.0% | 0.01% | -40.0% |
| Q1 2022 | $1,680,000 | -32.9% | 118,378 | 0.0% | 0.01% | -16.7% |
| Q4 2021 | $2,504,000 | -5.4% | 118,378 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $2,646,000 | -9.9% | 118,378 | 0.0% | 0.01% | -7.7% |
| Q2 2021 | $2,937,000 | -14.5% | 118,378 | 0.0% | 0.01% | -13.3% |
| Q1 2021 | $3,434,000 | +12.4% | 118,378 | 0.0% | 0.02% | +25.0% |
| Q4 2020 | $3,054,000 | -24.7% | 118,378 | -10.2% | 0.01% | -25.0% |
| Q3 2020 | $4,058,000 | – | 131,788 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |